QCG
FHTX icon

Quadrant Capital Group’s Foghorn Therapeutics FHTX Stock Holding History

Quadrant Capital Group’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-89
Closed -$2K – 2550
2021
Q4 		$2K Hold
89
– – ﹤0.01% 2127
2021
Q3 		$1K Buy
+89
New +$986 ﹤0.01% 2295

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Quadrant Capital Group's FHTX Position: Q1 2022 in Review

Quadrant Capital Group sold out of Foghorn Therapeutics (FHTX) in Q1 2022, closing a stake of 89 shares — an estimated $2K sold.

Quadrant Capital Group first reported a position in FHTX in Q3 2021 and held it in 2 quarters. The position peaked at $2K in Q4 2021. 61 funds tracked by Wall St. Rank hold FHTX as of Q1 2022.

  • Quadrant Capital Group reported no remaining Foghorn Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Quadrant Capital Group sold 89 Foghorn Therapeutics shares in Q1 2022, an estimated $2K.
  • Quadrant Capital Group first reported a position in Foghorn Therapeutics in Q3 2021 and held it in 2 quarters.
  • Quadrant Capital Group's Foghorn Therapeutics position peaked at $2K in Q4 2021.
  • 61 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2022.

Based on Quadrant Capital Group's 13F filing for Q1 2022, filed 6 May 2022.